---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-168597"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:47:19.924261+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lyell reports 40% ORR in TNBC from Phase 1 LYL797; expands into ovarian cancer

## Summary
- ORR of 40% and CBR of 60% at 150e6 CAR T dose in relapsed/refractory TNBC (n=5).
- No dose-limiting toxicities in patients without lung involvement; pneumonitis managed with prophylactic steroids.
- CAR T cells enhanced with anti-exhaustion technology showed expansion, infiltration, and persistence in solid tumors.
- Trial expanded to ROR1+ ovarian/endometrial cancer; new trial for multiple myeloma/CLL planned.
- IND submitted for LYL119, next-gen ROR1 CAR T candidate; expected to enter clinic this year.

## SEC filing metadata
- accession: 0001193125-24-168597
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524168597/0001193125-24-168597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524168597/d808272d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-168597
- JSON: https://secwatch.observer/filing/0001193125-24-168597.json
- Plain text: https://secwatch.observer/filing/0001193125-24-168597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.